A detailed history of Parallel Advisors, LLC transactions in Cure Vac N.V. stock. As of the latest transaction made, Parallel Advisors, LLC holds 2,303 shares of CVAC stock, worth $8,866. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,303
Previous 2,896 20.48%
Holding current value
$8,866
Previous $9,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$2.74 - $3.79 $1,624 - $2,247
-593 Reduced 20.48%
2,303 $6,000
Q2 2024

Aug 08, 2024

BUY
$2.31 - $4.99 $5,086 - $10,987
2,202 Added 317.29%
2,896 $9,000
Q1 2024

May 06, 2024

BUY
$2.94 - $4.34 $2,040 - $3,011
694 New
694 $2,000
Q3 2023

May 20, 2024

BUY
$6.5 - $10.77 $149 - $247
23 Added 3.59%
664 $4,000
Q3 2023

Nov 13, 2023

BUY
$6.5 - $10.77 $149 - $247
23 Added 3.59%
664 $4,000
Q2 2023

May 20, 2024

BUY
$6.69 - $12.25 $2,669 - $4,887
399 Added 164.88%
641 $6,000
Q2 2023

Aug 04, 2023

BUY
$6.69 - $12.25 $2,669 - $4,887
399 Added 164.88%
641 $6,000
Q1 2023

May 20, 2024

SELL
$6.38 - $12.5 $2,883 - $5,650
-452 Reduced 65.13%
242 $1,000
Q1 2023

Apr 25, 2023

BUY
$6.38 - $12.5 $1,543 - $3,025
242 New
242 $1,000
Q3 2022

Nov 10, 2022

SELL
$7.48 - $15.24 $1,428 - $2,910
-191 Reduced 63.04%
112 $1,000
Q2 2022

Aug 01, 2022

SELL
$13.18 - $19.41 $210 - $310
-16 Reduced 5.02%
303 $4,000
Q1 2022

Apr 28, 2022

BUY
$14.73 - $35.25 $117 - $282
8 Added 2.57%
319 $6,000
Q4 2021

Jan 20, 2022

BUY
$33.72 - $48.22 $7,789 - $11,138
231 Added 288.75%
311 $11,000
Q2 2021

Aug 06, 2021

BUY
$56.91 - $127.53 $2,731 - $6,121
48 Added 150.0%
80 $6,000
Q1 2021

Apr 23, 2021

BUY
$79.79 - $126.29 $2,553 - $4,041
32 New
32 $3,000

Others Institutions Holding CVAC

About CureVac N.V.


  • Ticker CVAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,467,008
  • Market Cap $722M
  • Description
  • CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...
More about CVAC
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.